All bio-rad controls with ca 19.9 were within the normal ranges.Siemens healthcare diagnostics is investigating the cause of the discordant ca19-9 results.The ifu states in the limitations section: "warning: do not use the advia centaur ca 19-9 assay as a screening test or for diagnosis.Do not predict disease recurrence solely on levels of advia centaur ca 19-9.Normal levels of advia centaur ca 19-9 do not always preclude the presence of disease.Note: do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals.Additionally, elevated levels of ca 19-9 can be observed in patients with nonmalignant diseases.Measurements of ca 19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.Therefore, it is important to use assayspecific values to evaluate quality control results." mdr 1219913-2019-00275 (initial result) was filed for the same event.
|
Siemens filed the initial mdr 1219913-2019-00276 on december 19, 2019.01/09/2020 additional information: the initial issue was reported as advia centaur xp ca19-9 patient's results were abnormally high with lot 445.Siemens cannot definitively determine the cause of this discordant result.Contributing factors such as sample integrity or preanalytical variables cannot be ruled out.Quality control was in range and no issues were noted with other patient samples indicating that the instrument and reagents were performing acceptably.There is a possibility that this represents a heterophilic (hama) interference which we know can occur in any immunoassay despite the presence of blocker substances (mouse serum and bgg in centaur ca19-9).Siemens received response from region the hbt cannot be provided in china, and no further testing can be conducted.The assay meets specification.The instrument is performing within specifications.No further evaluation of the device is required.Mdr 1219913-2019-00275 supplemental report 1 was filed for the same event.
|